Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Axitinib, sold under the brand name Inlyta, is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models and has shown partial responses in clinical trials with renal cell carcinoma (RCC) and several other tumour types.
Read the full article on WikipediaStage IV clear cell variant renal cell carcinoma (RCC) Clinical criteria: Treatment Phase: Continuing treatment beyond 3 months Patient must have received an initial authority prescription for this drug for this condition, AND Patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST), AND The treatment must be the sole PBS-subsidised therapy for this condition. Prescribers may request an increased maximum quantity sufficient to provide up to one month's supply for patients who require dose adjustment. A patient who has progressive disease when treated with this drug is no longer eligible for PBS-subsidised treatment with this drug.
“Its primary mechanism of action is thought to be vascular endothelial growth factor receptor 1–3, c-KIT and PDGFR inhibition, this, in turn, enables it to inhibit angiogenesis (the formation of new blood vessels by tumours).”
“2.5-6.1 hours”
Working under the parallel aged-care framework? Aged-care equivalent →